Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints

Recent advances in cardiovascular magnetic resonance (CMR) now allow the accurate and reproducible measurement of many aspects of cardiac and vascular structure and function, with prognostic data emerging for several key imaging biomarkers. These biomarkers are increasingly used in the evaluation of new drugs, devices and lifestyle modifications for the prevention and treatment of cardiovascular disease. This review outlines a conceptual framework for the application of imaging biomarkers to clinical trials, highlights several important CMR techniques which are in use in randomised studies, and reviews certain aspects of trial design, conduct and interpretation in relation to the use of CMR.

[1]  Chun Yuan,et al.  Association Between Carotid Plaque Characteristics and Subsequent Ischemic Cerebrovascular Events: A Prospective Assessment With MRI—Initial Results , 2006, Stroke.

[2]  Douglas G Altman,et al.  Comparison of protocols and registry entries to published reports for randomised controlled trials. , 2011, The Cochrane database of systematic reviews.

[3]  L. Härmark,et al.  Pharmacovigilance: methods, recent developments and future perspectives , 2008, European Journal of Clinical Pharmacology.

[4]  M. Robson,et al.  Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. , 2009, Journal of the American College of Cardiology.

[5]  R. Kim,et al.  Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study , 2003, The Lancet.

[6]  J. Ioannidis,et al.  Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias , 2008, PloS one.

[7]  Matthew D. Robson,et al.  Effects of Off-Pump Versus On-Pump Coronary Surgery on Reversible and Irreversible Myocardial Injury: A Randomized Trial Using Cardiovascular Magnetic Resonance Imaging and Biochemical Markers , 2004, Circulation.

[8]  J. Gimbel.  The safety of MRI scanning of pacemakers and ICDs: what are the critical elements of safe scanning? Ask me again at 10,000. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  U. Sechtem,et al.  Diagnostic value of perfusion cardiovascular magnetic resonance in patients with angina pectoris but normal coronary angiograms assessed by intracoronary acetylcholine testing , 2009, Heart.

[10]  Fei Liu,et al.  MRI of atherosclerosis in clinical trials , 2006, NMR in biomedicine.

[11]  Dorothee Auer,et al.  Detection of intraplaque hemorrhage by magnetic resonance imaging in symptomatic patients with mild to moderate carotid stenosis predicts recurrent neurological events. , 2008, Journal of vascular surgery.

[12]  R. Steeds,et al.  T2-weighted magnetic resonance imaging to assess myocardial oedema in ischaemic heart disease , 2009, Heart.

[13]  D. Grobbee,et al.  Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .

[14]  M. Sheppard,et al.  Validation of carotid arterial wall volume measurement by cardiovascular magnetic resonance , 2010, Journal of magnetic resonance imaging : JMRI.

[15]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[16]  V. Fuster,et al.  Effects of Lipid-Lowering by Simvastatin on Human Atherosclerotic Lesions: A Longitudinal Study by High-Resolution, Noninvasive Magnetic Resonance Imaging , 2001, Circulation.

[17]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.

[18]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[19]  Martin J Graves,et al.  The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. , 2009, Journal of the American College of Cardiology.

[20]  W S Kerwin,et al.  In Vivo Accuracy of Multispectral Magnetic Resonance Imaging for Identifying Lipid-Rich Necrotic Cores and Intraplaque Hemorrhage in Advanced Human Carotid Plaques , 2001, Circulation.

[21]  J. Francis,et al.  A Randomized Trial of On-Pump Beating Heart and Conventional Cardioplegic Arrest in Coronary Artery Bypass Surgery Patients With Impaired Left Ventricular Function Using Cardiac Magnetic Resonance Imaging and Biochemical Markers , 2008, Circulation.

[22]  S. Petersen,et al.  Myocardial injury following coronary artery surgery versus angioplasty (MICASA): a randomised trial using biochemical markers and cardiac magnetic resonance imaging. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[23]  T. Hackl,et al.  Diagnostic value of contrast-enhanced magnetic resonance imaging and single-photon emission computed tomography for detection of myocardial necrosis early after acute myocardial infarction. , 2007, Journal of the American College of Cardiology.

[24]  M. Robson,et al.  Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with 1.5-tesla. , 2007, Journal of the American College of Cardiology.

[25]  C Yuan,et al.  Analysis of the measurement precision of arterial lumen and wall areas using high‐resolution MRI , 2000, Magnetic resonance in medicine.

[26]  S. Prasad,et al.  Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy , 2007, Current cardiology reports.

[27]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[28]  V. Fuster,et al.  Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions: Two Years’ Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging , 2002, Circulation.

[29]  M. Pfeffer.  ACCORD(ing) to a trialist. , 2010, Circulation.

[30]  W. Rottbauer,et al.  Prognostic significance of cardiac magnetic resonance imaging: Update 2010. , 2010, Cardiology journal.

[31]  René M. Botnar,et al.  Age and Sex Distribution of Subclinical Aortic Atherosclerosis: A Magnetic Resonance Imaging Examination of the Framingham Heart Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[32]  Chun Yuan,et al.  Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. , 2008, American heart journal.

[33]  W. Kerwin,et al.  Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. , 2005, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[34]  O. Simonetti,et al.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. , 1999, Circulation.

[35]  Daniel C. Lee,et al.  Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study , 2007, Heart.

[36]  J. Ioannidis,et al.  Comparison of evidence of treatment effects in randomized and nonrandomized studies. , 2001, JAMA.

[37]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[38]  Jean-Claude Tardif,et al.  Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.

[39]  Jeffrey H Maki,et al.  Cardiovascular magnetic resonance imaging for valvular heart disease: technique and validation. , 2009, Circulation.

[40]  H. Grotenhuis,et al.  Validation and reproducibility of aortic pulse wave velocity as assessed with velocity‐encoded MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[41]  Sebastian Kelle,et al.  Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. , 2009, Journal of the American College of Cardiology.

[42]  D. Pennell,et al.  Cardiovascular magnetic resonance , 2001, Heart.

[43]  R. Kim,et al.  Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. , 2009, Journal of the American College of Cardiology.

[44]  R Peto,et al.  Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.

[45]  S. Neubauer,et al.  CMR for characterization of the myocardium in acute coronary syndromes , 2010, Nature Reviews Cardiology.

[46]  David Moher,et al.  CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials , 2010, PLoS medicine.

[47]  D. Grobbee,et al.  Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[48]  E. Nagel,et al.  High-resolution magnetic resonance myocardial perfusion imaging at 3.0-Tesla to detect hemodynamically significant coronary stenoses as determined by fractional flow reserve. , 2011, Journal of the American College of Cardiology.

[49]  A. Beek,et al.  Cardiovascular magnetic resonance imaging in patients with acute myocardial infarction , 2010, Heart.

[50]  Z. Fayad,et al.  Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. , 2005, Journal of the American College of Cardiology.

[51]  D J Pennell,et al.  Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. , 2000, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[52]  P. Herrero,et al.  Quantification of Regional Myocardial Oxygenation by Magnetic Resonance Imaging: Validation With Positron Emission Tomography , 2010, Circulation. Cardiovascular imaging.

[53]  Dudley J Pennell,et al.  Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[54]  Salim Yusuf,et al.  The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. , 2002, Journal of the American College of Cardiology.

[55]  Stephen B. Johnson,et al.  Central challenges facing the national clinical research enterprise. , 2003, JAMA.

[56]  A. Rossum,et al.  Use of cardiovascular magnetic resonance imaging in the assessment of left ventricular function, scar and viability in patients with ischaemic cardiomyopathy and chronic myocardial infarction , 2010, Heart.

[57]  R. Baggott.  DISEASE , 1947, Social Policy & Administration.

[58]  M. Robson,et al.  Cardiovascular magnetic resonance imaging for non-invasive assessment of vascular function: validation against ultrasound. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[59]  D. Pennell,et al.  A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance , 2007, Circulation.

[60]  Sebastian Kelle,et al.  Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. , 2007, The American journal of cardiology.

[61]  B. Gersh.  Thrombus Aspiration During Primary Percutaneous Coronary Intervention Improves Myocardial Reperfusion and Reduces Infarct Size: The EXPIRA (Thrombectomy With Export Catheter in Infarct-Related Artery During Primary Percutaneous Coronary Intervention) Prospective, Randomized Trial , 2010 .

[62]  Chun Yuan,et al.  MRI of carotid atherosclerosis: clinical implications and future directions , 2010, Nature Reviews Cardiology.

[63]  S. Solomon,et al.  Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy , 2009, Circulation.

[64]  J. Millet,et al.  Prognostic and therapeutic implications of dipyridamole stress cardiovascular magnetic resonance on the basis of the ischaemic cascade , 2008, Heart.

[65]  E. Lonn.  The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases , 2001, Pharmacoepidemiology and drug safety.

[66]  A. Lindsay,et al.  Form to function: current and future roles for atherosclerosis imaging in drug development , 2008, Nature Reviews Drug Discovery.

[67]  S. Neubauer,et al.  Magnetic resonance spectroscopy in myocardial disease. , 2009, JACC. Cardiovascular imaging.

[68]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[69]  Chun Yuan,et al.  In vivo accuracy of multisequence MR imaging for identifying unstable fibrous caps in advanced human carotid plaques , 2003, Journal of magnetic resonance imaging : JMRI.

[70]  M. Weir,et al.  The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .